Bleichroeder’s GeneDx Holdings WGS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$22K Hold
304
– – ﹤0.01% 107
2026
Q2
$20.9K Hold
304
– – ﹤0.01% 75
2026
Q1
$19.5K Hold
304
– – ﹤0.01% 77
2025
Q4
$39.5K Hold
304
– – 0.01% 68
2025
Q3
$32.8K Hold
304
– – 0.01% 65
2025
Q2
$28.1K Hold
304
– – 0.01% 68
2025
Q1
$26.9K Hold
304
– – 0.01% 70
2024
Q4
$23.4K Hold
304
– – 0.01% 69
2024
Q3
$12.9K Hold
304
– – ﹤0.01% 70
2024
Q2
$7.95K Hold
304
– – ﹤0.01% 72
2024
Q1
$2.78K Hold
304
– – ﹤0.01% 77
2023
Q4
$836 Hold
304
– – ﹤0.01% 76
2023
Q3
$1.11K Buy
304
+1
+0.3% +$5 ﹤0.01% 73
2023
Q2
$1.81K Hold
303
– – ﹤0.01% 82
2023
Q1
$3.65K Hold
303
– – ﹤0.01% 75
2022
Q4
$2.64K Sell
303
-3,030
-91% -$66.8K ﹤0.01% 79
2022
Q3
$97K Hold
3,333
– – 0.02% 61
2022
Q2
$139K Buy
3,333
+151
+5% +$10.2K 0.03% 63
2022
Q1
$322K Buy
3,182
+152
+5% +$16.9K 0.06% 72
2021
Q4
$446K Hold
3,030
– – 0.07% 70
2021
Q3
$759K Buy
+3,030
New +$1.04M 0.12% 57
2021
Q2
– Sell
-3,030
Closed -$1.49M – 93
2021
Q1
$1.49M Buy
+3,030
New +$1.58M 0.25% 42

Other funds holding WGS

Bleichroeder's WGS Position: Q3 2026 in Review

Bleichroeder held its GeneDx Holdings (WGS) position steady in Q3 2026 at 304 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #107.

Bleichroeder first reported a position in WGS in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.49M in Q1 2021. 152 funds tracked by Wall St. Rank hold WGS as of Q3 2026.

  • Bleichroeder held 304 shares of GeneDx Holdings worth $22K as of Q3 2026.
  • Bleichroeder left its GeneDx Holdings share count unchanged in Q3 2026.
  • GeneDx Holdings made up ﹤0.01% of Bleichroeder's portfolio in Q3 2026, its #107 holding.
  • Bleichroeder first reported a position in GeneDx Holdings in Q1 2021 and has held it in 22 quarters since.
  • Bleichroeder's GeneDx Holdings position peaked at $1.49M in Q1 2021.
  • 152 funds tracked by Wall St. Rank held GeneDx Holdings as of Q3 2026.

Based on Bleichroeder's 13F filing for Q3 2026, filed 13 Nov 2026.